Description
Tesamorelin is a growth-hormone-releasing hormone analog that stimulates the pituitary gland to increase the body’s natural production of growth hormone. This subsequently raises IGF-1 signaling and supports pathways involved in visceral-fat metabolism, body composition, tissue maintenance, lipid regulation, and muscle quality. Unlike compounds that supply growth hormone directly, tesamorelin works through the body’s existing endocrine system and preserves the natural signaling relationship between the hypothalamus, pituitary gland, and peripheral tissues.
Clinical research has demonstrated meaningful reductions in visceral abdominal fat, the metabolically active fat stored around the internal organs. Tesamorelin has also been studied for reductions in liver fat and improvements in body-composition measurements. Prescription tesamorelin, marketed as Egrifta SV and Egrifta WR, is used to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Its combination of established clinical use and powerful metabolic research potential has made tesamorelin a standout compound in body-composition, growth-hormone, visceral-fat, and longevity-clinic discussions.






Reviews
There are no reviews yet.